• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Roche’s Evrysdi offers sustained benefits in SMA extension trial in children

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 10, 2024 at 11:12: AM
via Roche has announced five-year findings from the open-label extension portion of the FIREFISH study, where Evrysdi (risdiplam) offered sustained efficacy and safety in children with type 1 spinal muscular atrophy (SMA).

article source
 




Top Bottom
Back
Quote